{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:16:50Z","timestamp":1788542210652,"version":"build-2803163510"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,10,1]]},"DOI":"10.2169\/internalmedicine.8772-21","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T22:09:54Z","timestamp":1647641394000},"page":"2973-2979","source":"Crossref","is-referenced-by-count":19,"title":["Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody"],"prefix":"10.2169","volume":"61","author":[{"given":"Ryohei","family":"Ono","sequence":"first","affiliation":[{"name":"Department of Cardiology, Matsudo City General Hospital, Japan"},{"name":"Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Iwai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Matsudo City General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Matsudo City General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Matsudo City General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Matsudo City General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Matsudo City General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Saotome","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Matsudo City General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29: 806-812, 2016.","DOI":"10.1097\/WCO.0000000000000391"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012.","DOI":"10.1038\/nrc3239"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Rota E, Varese P, Agosti S, et al. Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: a life-threatening continuum of neuromuscular and cardiac toxicity. eNeurologicalSci 14: 4-5, 2019.","DOI":"10.1016\/j.ensci.2018.11.023"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yamamoto AM, Gajdos P, Eymard B, et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 58: 885-890, 2001.","DOI":"10.1001\/archneur.58.6.885"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Romi F, Suzuki S, Suzuki N, Petzold A, Plant GT, Gilhus NE. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol 259: 1312-1316, 2012.","DOI":"10.1007\/s00415-011-6344-y"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Suzuki S, Utsugisawa K, Nagane Y, et al. Classification of myasthenia gravis based on autoantibody status. Arch Neurol 64: 1121-1124, 2007.","DOI":"10.1001\/archneur.64.8.1121"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4: 36, 2016.","DOI":"10.1186\/s40425-016-0139-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Norwood TG, Westbrook BC, Johnson DB, et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 5: 91, 2017.","DOI":"10.1186\/s40425-017-0296-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Thakolwiboon S, Karukote A, Wilms H. De novo myasthenia gravis induced by atezolizumab in a patient with urothelial carcinoma. Cureus 11: e5002, 2019.","DOI":"10.7759\/cureus.5002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sekiguchi K, Hashimoto R, Noda Y, et al. Diaphragm involvement in immune checkpoint inhibitor-related myositis. Muscle Nerve 60: E23-E25, 2019.","DOI":"10.1002\/mus.26640"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fazel M, Jedlowski PM. Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma. Case Rep Immunol 2019: 2539493, 2019.","DOI":"10.1155\/2019\/2539493"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Takahashi S, Mukohara S, Hatachi S, Yamashita M, Kumagai S. A case of myositis with dropped head syndrome and anti-titin antibody positivity induced by pembrolizumab. Scand J Rheumatol 49: 509-511, 2020.","DOI":"10.1080\/03009742.2020.1760346"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Onda A, Miyagawa S, Takahashi N, et al. Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy. Intern Med 58: 1635-1638, 2019.","DOI":"10.2169\/internalmedicine.1956-18"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Jeyakumar N, Etchegaray M, Henry J, et al. The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma. Case Rep Immunol 2020: 5126717, 2020.","DOI":"10.1155\/2020\/5126717"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Schiopu SRI, Kasmann L, Schonermarck U, et al. Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy - case report. Transl Lung Cancer Res 10: 1039-1046, 2021.","DOI":"10.21037\/tlcr-20-1095"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gonzalez NL, Puwanant A, Lu A, Marks SM, Zivkovic SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord 27: 266-268, 2017.","DOI":"10.1016\/j.nmd.2017.01.002"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Suzuki S, Utsugisawa K, Nagane Y, Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011: 740583, 2011.","DOI":"10.4061\/2011\/740583"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Cheng W, Sun T, Liu C, et al. A systematic review of myasthenia gravis complicated with myocarditis. Brain Behav 11: e2242, 2021.","DOI":"10.1002\/brb3.2242"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91: e985-e994, 2018.","DOI":"10.1212\/WNL.0000000000006124"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fazal M, Prentice DA, Kho LK, Fysh E. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies. Intern Med J 50: 1003-1006, 2020.","DOI":"10.1111\/imj.14946"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/19\/61_8772-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:21:00Z","timestamp":1715232060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/19\/61_8772-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":20,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8772-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]},"article-number":"8772-21"}}